Buprenorphine HCl NDC 31722-870

NDC codes

FDA NDC Directory

Product NDC (as listed)31722-870Labeler and product segments. Claims need a package NDC.

Product NDC at billing width31722-0870Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
31722-870-30	31722087030	30 TABLET in 1 BOTTLE (31722-870-30)Marketed from Jan 12, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Buprenorphine HCl
Generic name (nonproprietary): buprenorphine hcl
Active ingredients: Buprenorphine hydrochloride — 2 mg/1
Dosage form: Tablet
Route: Sublingual
Labeler: Camber Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 219401
Marketing start: Jan 12, 2026
Listing expires: Dec 31, 2027
DEA schedule: CIII
Other FDA classes: Partial Opioid Agonists (Mechanism)
Identifiers: Product ID 31722-870_80bd7b21-6679-4dbb-84dd-f755c7a90166SPL ID 80bd7b21-6679-4dbb-84dd-f755c7a90166SPL set ID b52cea0e-688f-4beb-bf7d-f228b81dbd23RxCUI 351264, 351265UNII 56W8MW3EN1UPC 0331722871303, 0331722870306
Pharmacologic class: Partial Opioid Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Sublingual products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N431722087030 followed by a unit qualifier and the quantity

Package 31722-0870-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 23, 2026.

Indications (excerpt from the label)

Buprenorphine sublingual tablets are indicated for the treatment of opioid dependence and is preferred for induction. Buprenorphine sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support. Buprenorphine sublingual tablets, contain buprenorphine, a partial opioid agonist, and is indicated for the treatment of opioid dependence and is preferred for induction. (1) Buprenorphine sublingual tablets should be used as part of a complete treatment plan that includes counseling and psychosocial support. (1)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 219401

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 219401
Product	Strength	Form · route	Labeler	Product NDC
Buprenorphine HCl	Buprenorphine hydrochloride 8 mg/1	TabletSublingual	Camber Pharmaceuticals, Inc.	31722-871